Aphea.Bio is a technology company.
Aphea.Bio develops biocontrol and biostimulant products by harnessing the diversity of microorganisms through our APEXbio™ R&D platform. They create natural solutions for agriculture.
Aphea.Bio has raised $99.0M across 2 funding rounds.
Aphea.Bio has raised $99.0M in total across 2 funding rounds.
Aphea.Bio has raised $99.0M in total across 2 funding rounds.
Aphea.Bio's investors include Astanor Ventures, Energy Impact Partners.
Aphea.Bio is a Belgium-based agtech company that discovers, develops, and commercializes biological products like biostimulants and biocontrols for sustainable agriculture, targeting major row crops such as maize and wheat.[2][1][3] These microbial solutions reduce fertilizer use, control fungal diseases, and enhance crop yields through seed treatments or sprays, serving conventional and organic farmers while integrating with existing practices to improve soil health and biodiversity.[1][2][4] With a research-driven approach via its APEXbio™ platform, the company has grown from a 2017 VIB spin-off to 30 employees, closed a €19.8 million Series B, and launched products like ACTIV by APHEA bio® in markets such as Poland, backed by investors including Innovation Industries, Astanor, V-Bio Ventures, and the Gates Foundation.[1][2][6][7]
Aphea.Bio spun out from VIB (Flanders Institute for Biotechnology) in July 2017, establishing greenhouse and lab facilities at the Bioaccelerator in Technologiepark Gent, Belgium.[2][5][8] Key early involvement came from VIB scientist Jeroen Raes, renowned for microbiome mapping in human guts and oceans, who contributed algorithms for soil microbiome analysis in wheat and maize.[8] The founding team secured €7.7 million in Series A funding to build discovery pipelines for biostimulants and biocontrols, filing initial IP and running first field trials.[2] Pivotal moments included exceeding 10k unique microbial strains, facility expansions, Series B funding of €19.8 million ($16.6 million, led by Astanor), and Gates Foundation Series C support in 2023 for smallholder farmers in Sub-Saharan Africa and South Asia.[2][6][7]
Aphea.Bio stands out in ag biotech through its integrated APEXbio™ R&D platform, which accelerates microbial discovery by combining bioinformatics, microbiome mapping, advanced culturing (up to 40% of soil microbes vs. industry 10-15%), algorithmic screening, climate chambers, and automated phenotyping.[3][8][9][2] This enables high-throughput pipelines for biostimulants, biofungicides (with field trials completed), and emerging bioinsecticides/bioherbicides.[1][2][3]
Aphea.Bio rides the global shift toward sustainable agriculture, addressing fertilizer reduction mandates (e.g., EU targets), pesticide resistance, and soil degradation amid climate change and food security pressures for row crops.[1][4][7] Its timing aligns with surging demand for biologicals—projected to grow as regulations curb chemicals—positioned in Ghent's biotech hub alongside peers like Biotalys.[7] Market forces like smallholder needs in Africa/Asia (Gates-backed) and integrated pest management favor its scalable, cost-effective microbes over synthetics.[6][7] The company influences the ecosystem by pioneering microbiome tech akin to human pharma, enabling precise, eco-friendly alternatives that complement precision ag tools, driving broader adoption of biologics in conventional farming.[3][7][8]
Aphea.Bio is poised to commercialize more pipeline products, targeting market entry for biofungicides and expanding bioinsecticide/herbicide lines while scaling for smallholders and new crops.[2][3][6] Trends like AI-driven discovery, regulatory tailwinds for biologics, and portfolio synergies (e.g., with Vivent/MagGrow) will accelerate growth, potentially leading to Series C exits or IPOs as it hits field-validated milestones.[7][8] Its influence may evolve from R&D innovator to go-to microbial provider, reshaping ag inputs toward biology and amplifying Ghent's role in Europe's ag biotech surge—transforming sustainable farming from niche to norm, as its founding mission envisioned.[3][4]
Aphea.Bio has raised $99.0M across 2 funding rounds. Most recently, it raised $77.0M Series C in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $77.0M Series C | Astanor Ventures, Energy Impact Partners | |
| Apr 1, 2021 | $22.0M Series B | Astanor Ventures, Energy Impact Partners |